In melanoma, radiosurgery may combine well with immunotherapy, especially PD-1 inhibitors

June 25, 2018, CU Anschutz Medical Campus

Doctors often treat melanoma with drugs that unblind the immune system to cancer. And brain metastases associated with melanoma are often treated with precisely targeted radiation known as radiosurgery. Now a University of Colorado Cancer Center study published in the Journal of Neuro-Oncology shows a potential advantage of combining these two techniques: Of 38 melanoma patients treated with immunotherapy and radiosurgery between 2012 and 2017, median overall survival was not reached, meaning that so many of these patients (who historically have had very poor prognosis) were still alive when data was analyzed that it was impossible to predict how long a patient treated in this way would be expected to live. Importantly, the study also shows a significant difference in cancer control depending on the type of immunotherapy used. In melanoma, brain metastases are a major cause of mortality. Patients treated with anti-CTLA4 immunotherapies saw the development of new brain metastases at median 3.1 months, whereas the median was not reached for patients treated with anti-PD-1 immunotherapies.

"We decided to look at this because it's something we commonly do in the clinic. We use immune checkpoint inhibitors, and at the appearance of metastases, we're using radiosurgery. Big studies have shown a dramatic increase in survival for patients with , and our study hints at one possible reason why: There may be an underlying synergy between these therapies," says Tyler Robin, MD, Ph.D., senior resident in at the CU School of Medicine and the paper's first author.

The exact mechanism of this synergy is still under investigation, but studies have shown that radiation treatments can increase the PD-L1 signal on tumors essentially giving the anti-PD-1 or anti-PD-L1 inhibitors a target to act on.

Of the 38 patients treated in this way, none developed severe side effects, though six patients experienced some adverse reaction. Twenty-five patients received anti-CTLA4 immunotherapy, while 13 received anti-PD-1 immunotherapy, with results for anti-PD-1 therapies being across-the-board more successful (full results here).

"Several years ago, a patient might have expected to live months after that diagnosis, but for many this is no longer the case," Robin says. "People are actively investigating the combination of immune checkpoint inhibits and radiation, and our data raise the possibility that PD-1 inhibitors are preferential in this setting. We hope that ongoing and future investigations will shed more light on the potential value of this combination."

Explore further: Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

More information: Tyler P. Robin et al, Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases, Journal of Neuro-Oncology (2018). DOI: 10.1007/s11060-018-2930-5

Related Stories

Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

September 21, 2016
Brain metastases are one of the most common complications of advanced melanoma, requiring multidisciplinary management. Patients who are diagnosed with these metastases have an expected median survival of only 4 to 5 months. ...

Is whole-brain radiation still best for brain metastases from small-cell lung cancer?

April 16, 2018
Lung cancer often metastasizes to the brain. Historically, brain metastases have been treated with whole-brain radiation therapy. However, whole-brain radiation is associated with cognitive side-effects and studies of non-small ...

Combining targeted radionuclide therapy and immunotherapy could improve melanoma survival

June 25, 2018
Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows that combining targeted radionuclide therapy with immunotherapy could improve the survival of patients with ...

Radiosurgery or whole-brain radiation in patients with multiple brain metastases?

December 18, 2017
Although targeted therapies have produced dramatic advances in our ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits ...

Older melanoma patients have better response to immune checkpoint blockade therapy

June 13, 2018
Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The ...

Combination of radiation and immune checkpoint therapy holds potential for lung cancer

March 16, 2017
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors (ICPIs) to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side ...

Recommended for you

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.